Propranolol versus nadolol for treatment of pediatric subglottic hemangioma.

Abstract

PURPOSE\nThe beta-blocker propranolol is the standard medical therapy for subglottic hemangioma (SGH), but side effects and incomplete response rates require close monitoring. Nadolol has been identified as a potential alternative but its use has not been examined for SGH.\n\n\nMETHODS\nSingle institution retrospective cohort study of pediatric SGH treated with propranolol or nadolol.\n\n\nRESULTS\nThirteen children (1 male, 12 female) with SGH were included: 6 were treated with propranolol (2.0-3.5\xa0mg/kg/d) and 7 with nadolol (2.0-4.0\xa0mg/kg/d). The most common presenting symptom was stridor (85%) and mean (SD) symptom duration prior to diagnosis was 4.6 (3.8) weeks. Cutaneous vascular lesions were present in 54%. There were 7 right-sided, 5 left-sided and 1 bilateral SGH. The mean (SD) percentage of airway obstruction was 60.6% (27.4). The response rate was 100% (6/6) for propranolol and 85.7% (6/7) for nadolol (p\xa0=\xa00.36). Mean (SD) time to symptomatic improvement was 2.6 (2.2) days with no difference across groups (p\xa0=\xa00.71). There was no hypotension, hypoglycemia, weight loss, or sleep disturbances in either group. One patient in the propranolol group experienced vomiting. Two patients in the nadolol group required dosage reduction due to asymptomatic bradycardia. The mean (SD) duration of admission was 14.4 (12.6) days and duration of treatment was 13.8 (11.2) days with no difference across groups (p\xa0=\xa00.23; p\xa0=\xa00.31, respectively). All patients had treatment initiated as inpatients and completed as outpatients.\n\n\nCONCLUSION\nChildren with SGH treated with propranolol or nadolol had similar response rates and side effect profiles.